Urokinase quality: analysis of different preparations

Area of Science:

• Biochemistry
• Pharmacology
• Thrombolytic agents

Background:

• Urokinase (UK) is a vital thrombolytic enzyme.
• Assessing the quality of commercially available UK preparations is crucial for therapeutic efficacy.
• Variations in UK composition may impact its clinical performance.

Purpose of the Study:

• To evaluate the purity, fibrinolytic activity, and molecular weight distribution of five German Urokinase (UK) preparations.
• To compare the characteristics of high-molecular-weight UK (HMW-UK) and low-molecular-weight UK (LMW-UK) across different commercial products.
• To determine compliance with purity standards for UK therapeutics.

Main Methods:

• Analysis of fibrinolytic activity using standardized assays.
• Determination of molecular weight composition via electrophoresis or chromatography.
• Assessment of purity through tests for coagulative activity, lysozyme, endotoxins, protease activity, and HBs antigen.

Main Results:

• All preparations, except one (B), exhibited comparable fibrinolytic activity (91-107% of declared).
• Preparations A, D, and E were predominantly high-molecular-weight UK (HMW-UK) (82-86%).
• Preparation C consisted mainly of low-molecular-weight UK (LMW-UK) (95%), while preparation B had a mix of HMW-UK and LMW-UK (47:53).
• Preparation E met all purity criteria; A and C met them with restrictions.

Conclusions:

• Commercial Urokinase (UK) preparations exhibit significant variability in molecular weight composition (HMW-UK vs. LMW-UK).
• While fibrinolytic activity is generally consistent, the differing HMW-UK/LMW-UK ratios may have clinical implications.
• Preparation E demonstrated superior purity, with A and C also showing acceptable profiles under certain conditions.